Cure OGT
A foundation of Patients, Researchers and Clinicians around the world, joining forces to treat O-GlcNAc Transferase X-Linked Intellectual Disability OGT-XLID
Our Vision:
The Cure OGT Community envisions a world where individuals with OGT-XLID have access to the best possible care, support, and research opportunities.
We strive to create a community of empowered individuals, families, researchers, and clinicians working together to improve the lives of those affected by this rare condition.
Cure OGT at a Glance
Diagnosed with OGT-XLID?
The OGT Foundation Family Support Network has been created to help families connect and stand united to advance research and resources for OGT-XLID. Register today to join our network and make your voice heard for everyone affected by OGT-XLID.
News, publications and events
OGT Conference 2024: Critical Path to treating OGT-XLID
We are excited to announce OGT Conference 2024, the first-ever event dedicated to OGT-XLIC (also known as OGT-CDG). This landmark conference will bring together leading researchers, clinicians, and families to explore and discuss lates research
Grace Science, LLC Selected by FDA to Participate in the START Pilot Program for GS-100 Gene Therapy for NGLY1 Deficiency and Announcement of the Successful Treatment of the 2nd Patient
Grace Science, LLC Selected by FDA to Participate in the START Pilot Program for GS-100 Gene Therapy for NGLY1 Deficiency and Announcement of the Successful Treatment of the 2nd Patient Grace Science, LLC announced today
New Research Paper: A Novel Mouse Model Sheds Light on OGT-CDG Pathophysiology
Latest work of Daan van Aalten Lab at Molecular Biology & Genetics – Aarhus University by Florence Authier, PhD, Andrew Ferenbach in collaboration with Nina Ondruskova and Alison McNeilly (dundee) on trying to understand the
CAD mutations and uridine-responsive epileptic encephalopathy
Abstract Unexplained global developmental delay and epilepsy in childhood pose a major socioeconomic burden. Progress in defining the molecular bases does not often translate into effective treatment. Notable exceptions include certain inborn errors of metabolism
Massively targeted evaluation of therapeutic CRISPR off-targets in cells
Abstract Methods for sensitive and high-throughput evaluation of CRISPR RNA-guided nucleases (RGNs) off-targets (OTs) are essential for advancing RGN-based gene therapies. Here we report SURRO-seq for simultaneously evaluating thousands of therapeutic RGN OTs in cells.
The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer
In a study recently published in Nature Medicine, Lu et al. examined the feasibility and safety of using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-engineered, patient-derived T cells to treat late-stage lung cancer.
Our Community:
Patients
Our patients are at the heart of our mission, sharing their experiences to propel research and drive awareness for OGT-XLID.
Researchers
Forward-thinking researchers lead the charge in unraveling the complexities of OGT-XLID and forging new pathways to innovative treatments.
Clinicians
Clinicians familiar with OGT-XLID provide specialized medical knowledge and compassionate care to ensure the best quality of life for our community members.
Get Involved
Your support of the Cure OGT fuels groundbreaking research into OGT-XLID, paving the way for transformative treatments and a healthier future.
Donate
Visit our dedicated Give Lively donation platform by clicking HERE.
Host an event
Fundraisers are a great way to raise OGT-XLID awareness in your community and raise funds for a cause!
Volunteer your time
We need community members and parents willing to become involved with our organization.
Join the Board
We are continually looking for additional individuals willing to serve on our Medical Advisory Board.
Share your story
Inspire other families, researchers and clinicians by sharing a personal story.
Join our community
Help raise awareness of Cure OGT by joining and participating in our activities.